Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Sareum Hldgs Plc
SARSareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom. Address: Langford Arch, Cambridge, United Kingdom, CB22 3FX
Analytics
WallStreetin tavoitehinta
138.96 GBPP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut SAR
Osinkoanalytiikka SAR
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria SAR
Osakkeen arvostus SAR
Talousasiat SAR
Tuloksia | 2019 | Dynamiikka |